What is Schreiber Allergy?
Based in Rockville, Schreiber Allergy operates as a premier medical practice dedicated to the comprehensive treatment of food allergies, asthma, eczema, hives, and medication sensitivities. The clinic distinguishes itself through the application of advanced immunology protocols, most notably oral immunotherapy (OIT) for high-risk food allergies including peanut, tree nut, and milk sensitivities. By integrating state-of-the-art diagnostic tools with a patient-centric, compassionate care philosophy, the practice serves both pediatric and adult populations, effectively bridging the gap between clinical research and daily patient management. Their market position is defined by a commitment to evidence-based outcomes and specialized care, which has become increasingly vital as the prevalence of allergic diseases continues to rise globally.
How much funding has Schreiber Allergy raised?
Schreiber Allergy has raised a total of $113K across 1 funding round:
Debt
$113K
Debt (2021): $113K with participation from PPP
Key Investors in Schreiber Allergy
PPP
Public-Private Partnership
What's next for Schreiber Allergy?
The recent capital injection is expected to catalyze the next phase of growth for Schreiber Allergy, focusing on the expansion of its clinical footprint and the optimization of its therapeutic offerings. As the organization transitions through this late-stage funding cycle, strategic priorities will likely include the scaling of its OIT programs and the potential integration of digital health solutions to monitor patient progress more effectively. By leveraging this financial support, the practice aims to solidify its reputation as a leader in allergy management, ensuring that its specialized medical services remain accessible to a broader demographic while maintaining the high standards of personal attention that define its current operational success.
See full Schreiber Allergy company page
